Bright Minds Biosciences Azioni (NASDAQ: DRUG)

Ultime notizie per Bright Minds Biosciences (NASDAQ:DRUG) Azioni

Bright Minds Biosciences

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences Inc

DRUG FREE SOLUTION INC by Drug Free Solution Inc.

Drug Free Solution Inc

Drugs Made In America Acquisition Corp

<p>SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect SmartFinancial to report an <strong>earnings per share</strong> (EPS) of $0.47.</p>
<p>The market awaits SmartFinancial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.07, leading to a 3.43% increase in the share price the following trading session.</p>
<p>Here's a look at SmartFinancial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.39</td>
<td>0.41</td>
<td>0.41</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.46</td>
<td>0.49</td>
<td>0.41</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275977_0.png" alt="eps graph" /></p>
<h3>Tracking SmartFinancial's Stock Performance</h3>
<p>Shares of SmartFinancial were trading at $31.5 as of October 17. Over the last 52-week period, shares are up 54.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SMBK/earnings"><strong>To track all earnings releases for SmartFinancial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

SMBK

Earnings Outlook For SmartFinancial

<p>Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Preferred Bank to report an <strong>earnings per share</strong> (EPS) of $2.38.</p>
<p>The market awaits Preferred Bank's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 4.68% increase in the share price on the following day.</p>
<p>Here's a look at Preferred Bank's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.39</td>
<td>2.38</td>
<td>2.54</td>
<td>2.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.48</td>
<td>2.44</td>
<td>2.60</td>
<td>2.71</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>-0.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275961_0.png" alt="eps graph" /></p>
<h3>Tracking Preferred Bank's Stock Performance</h3>
<p>Shares of Preferred Bank were trading at $85.08 as of October 17. Over the last 52-week period, shares are up 39.82%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PFBC/earnings"><strong>To track all earnings releases for Preferred Bank visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PFBC

Insights into Preferred Bank's Upcoming Earnings

<p>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate HealthStream to report an <strong>earnings per share</strong> (EPS) of $0.12.</p>
<p>Anticipation surrounds HealthStream's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.04, leading to a 4.04% drop in the share price on the subsequent day.</p>
<p>Here's a look at HealthStream's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.12</td>
<td>0.11</td>
<td>0.10</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.16</td>
<td>0.17</td>
<td>0.15</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>15.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275952_0.png" alt="eps graph" /></p>
<h3>Performance of HealthStream Shares</h3>
<p>Shares of HealthStream were trading at $28.93 as of October 17. Over the last 52-week period, shares are up 31.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on HealthStream</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on HealthStream.</p>
<p>HealthStream has received a total of 1 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $28.0, the consensus suggests a potential 3.21% downside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Simulations Plus, Phreesia and Definitive Healthcare, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Simulations Plus received a Outperform consensus from analysts, with an average 1-year price target of $47.0, implying a potential 62.46% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Phreesia, with an average 1-year price target of $29.4, implying a potential 1.62% upside.</li>
<li>Definitive Healthcare is maintaining an Neutral status according to analysts, with an average 1-year price target of $5.61, indicating a potential 80.61% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Simulations Plus, Phreesia and Definitive Healthcare are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$47.82M</td>
<td>1.20%</td>
</tr>
<tr>
<td>Simulations Plus</td>
<td>Outperform</td>
<td>14.23%</td>
<td>$13.26M</td>
<td>1.75%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>4.56%</td>
<td>$50.45M</td>
<td>-28.39%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>HealthStream ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, HealthStream is at the top among its peers. However, its return on equity is at the bottom compared to the others.</p>
<h3>About HealthStream</h3>
<p>HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.</p>
<h3>HealthStream's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> HealthStream's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>3.41%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> HealthStream's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.82%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> HealthStream's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.2%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> HealthStream's ROA excels beyond industry benchmarks, reaching <strong>0.82%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> HealthStream's debt-to-equity ratio is below the industry average at <strong>0.05</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/HSTM/earnings"><strong>To track all earnings releases for HealthStream visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HSTM

Earnings Preview For HealthStream

<p><strong>RLI</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that RLI will report an <strong>earnings per share</strong> (EPS) of $0.99. </p>
<p>Investors in RLI are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.38 in the last quarter, leading to a 2.95% increase in the share price on the following day.</p>
<p>Here's a look at RLI's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.34</td>
<td>1.60</td>
<td>1.49</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.72</td>
<td>1.89</td>
<td>1.54</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>3.0%</td>
<td>-4.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275942_0.png" alt="eps graph" /></p>
<h3>Performance of RLI Shares</h3>
<p>Shares of RLI were trading at $164.21 as of October 17. Over the last 52-week period, shares are up 26.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RLI/earnings"><strong>To track all earnings releases for RLI visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RLI's Earnings: A Preview

<p>HBT Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBT#NASDAQ">HBT</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that HBT Finl will report an <strong>earnings per share</strong> (EPS) of $0.57.</p>
<p>HBT Finl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 3.56% increase in the share price on the subsequent day.</p>
<p>Here's a look at HBT Finl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.56</td>
<td>0.55</td>
<td>0.59</td>
<td>0.58</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.57</td>
<td>0.57</td>
<td>0.60</td>
<td>0.63</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275933_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of HBT Finl were trading at $23.1 as of October 17. Over the last 52-week period, shares are up 27.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HBT/earnings"><strong>To track all earnings releases for HBT Finl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into HBT Finl's Upcoming Earnings

<p><strong>Trustco Bank</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRST#NASDAQ">TRST</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Trustco Bank will report an <strong>earnings per share</strong> (EPS) of $0.00. </p>
<p>Anticipation surrounds Trustco Bank's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.13, which was followed by a 5.12% increase in the share price the next day.</p>
<p>Here's a look at Trustco Bank's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.53</td>
<td>0.60</td>
<td>0.66</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.66</td>
<td>0.64</td>
<td>0.52</td>
<td>0.77</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275924_0.png" alt="eps graph" /></p>
<h3>Trustco Bank Share Price Analysis</h3>
<p>Shares of Trustco Bank were trading at $34.49 as of October 17. Over the last 52-week period, shares are up 32.47%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TRST/earnings"><strong>To track all earnings releases for Trustco Bank visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TRST

A Look Ahead: Trustco Bank's Earnings Forecast

<p><strong>Great Ajax</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJX#NYSE">AJX</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Great Ajax will report an <strong>earnings per share</strong> (EPS) of $-0.38. </p>
<p>The market awaits Great Ajax's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.09, leading to a 5.16% drop in the share price the following trading session.</p>
<p>Here's a look at Great Ajax's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.15</td>
<td>0.02</td>
<td>0.20</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.24</td>
<td>-0.16</td>
<td>-0.07</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-3.0%</td>
<td>-14.000000000000002%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275907_0.png" alt="eps graph" /></p>
<h3>Market Performance of Great Ajax's Stock</h3>
<p>Shares of Great Ajax were trading at $3.24 as of October 17. Over the last 52-week period, shares are down 26.3%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/AJX/earnings"><strong>To track all earnings releases for Great Ajax visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Great Ajax's Earnings Preview

<p><strong>Dynex Cap</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DX#NYSE">DX</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Dynex Cap will report an <strong>earnings per share</strong> (EPS) of $-0.02. </p>
<p>Dynex Cap bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.07, which was followed by a 1.06% increase in the share price the next day.</p>
<p>Here's a look at Dynex Cap's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.19</td>
<td>-0.09</td>
<td>-0.20</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.12</td>
<td>-0.30</td>
<td>-0.24</td>
<td>-0.28</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275898_0.png" alt="eps graph" /></p>
<h3>Dynex Cap Share Price Analysis</h3>
<p>Shares of Dynex Cap were trading at $12.66 as of October 17. Over the last 52-week period, shares are up 23.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/DX/earnings"><strong>To track all earnings releases for Dynex Cap visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring Dynex Cap's Earnings Expectations

<p>AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that AGNC Investment will report an <strong>earnings per share</strong> (EPS) of $0.51.</p>
<p>AGNC Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 0.68% increase in the share price on the subsequent day.</p>
<p>Here's a look at AGNC Investment's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.57</td>
<td>0.58</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.53</td>
<td>0.58</td>
<td>0.60</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275890_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of AGNC Investment were trading at $10.46 as of October 17. Over the last 52-week period, shares are up 30.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/AGNC/earnings"><strong>To track all earnings releases for AGNC Investment visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AGNC

Earnings Outlook For AGNC Investment

<p>Washington Trust Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WASH#NASDAQ">WASH</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Washington Trust Bancorp will report an <strong>earnings per share</strong> (EPS) of $0.56.</p>
<p>The announcement from Washington Trust Bancorp is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.14, which was followed by a 5.62% increase in the share price the next day.</p>
<p>Here's a look at Washington Trust Bancorp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.49</td>
<td>0.45</td>
<td>0.57</td>
<td>0.58</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.63</td>
<td>0.64</td>
<td>0.76</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275881_0.png" alt="eps graph" /></p>
<h3>Tracking Washington Trust Bancorp's Stock Performance</h3>
<p>Shares of Washington Trust Bancorp were trading at $33.7 as of October 17. Over the last 52-week period, shares are up 34.42%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WASH/earnings"><strong>To track all earnings releases for Washington Trust Bancorp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


WASH

Washington Trust Bancorp's Earnings: A Preview

<p><strong>Cadence Bank</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Cadence Bank will report an <strong>earnings per share</strong> (EPS) of $0.64. </p>
<p>Investors in Cadence Bank are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.08 in the last quarter, leading to a 3.93% increase in the share price on the following day.</p>
<p>Here's a look at Cadence Bank's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.61</td>
<td>0.55</td>
<td>0.53</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.62</td>
<td>0.40</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>4.0%</td>
<td>-6.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275856_0.png" alt="eps graph" /></p>
<h3>Cadence Bank Share Price Analysis</h3>
<p>Shares of Cadence Bank were trading at $33.5 as of October 17. Over the last 52-week period, shares are up 68.26%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CADE/earnings"><strong>To track all earnings releases for Cadence Bank visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CADE

Insights Ahead: Cadence Bank's Quarterly Earnings

<p><strong>BOK Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BOK Financial will report an <strong>earnings per share</strong> (EPS) of $1.98. </p>
<p>The market awaits BOK Financial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.32, leading to a 0.74% drop in the share price on the subsequent day.</p>
<p>Here's a look at BOK Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>1.73</td>
<td>1.75</td>
<td>2.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.02</td>
<td>1.91</td>
<td>1.76</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275845_0.png" alt="eps graph" /></p>
<h3>Performance of BOK Financial Shares</h3>
<p>Shares of BOK Financial were trading at $114.66 as of October 17. Over the last 52-week period, shares are up 57.28%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BOKF/earnings"><strong>To track all earnings releases for BOK Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BOKF

Uncovering Potential: BOK Financial's Earnings Preview

<p>Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Enterprise Finl Servs will report an <strong>earnings per share</strong> (EPS) of $1.14.</p>
<p>Enterprise Finl Servs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.15 in the last quarter, leading to a 12.37% increase in the share price on the following day.</p>
<p>Here's a look at Enterprise Finl Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.06</td>
<td>1.11</td>
<td>1.19</td>
<td>1.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.21</td>
<td>1.07</td>
<td>1.21</td>
<td>1.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275836_0.png" alt="eps graph" /></p>
<h3>Tracking Enterprise Finl Servs's Stock Performance</h3>
<p>Shares of Enterprise Finl Servs were trading at $53.85 as of October 17. Over the last 52-week period, shares are up 48.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EFSC/earnings"><strong>To track all earnings releases for Enterprise Finl Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


EFSC

Examining the Future: Enterprise Finl Servs's Earnings Outlook

<p><strong>Alexandria Real Estate</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Alexandria Real Estate will report an <strong>earnings per share</strong> (EPS) of $2.37. </p>
<p>Anticipation surrounds Alexandria Real Estate's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 3.52% drop in the share price on the subsequent day.</p>
<p>Here's a look at Alexandria Real Estate's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>2.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.36</td>
<td>2.35</td>
<td>2.28</td>
<td>2.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of Alexandria Real Estate's Stock</h3>
<p>Shares of Alexandria Real Estate were trading at $121.25 as of October 17. Over the last 52-week period, shares are up 28.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Alexandria Real Estate</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Alexandria Real Estate.</p>
<p>Alexandria Real Estate has received a total of 8 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $128.88, the consensus suggests a potential 6.29% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Ventas, Healthpeak Properties and Omega Healthcare Invts, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>For Ventas, analysts project an Outperform trajectory, with an average 1-year price target of $65.88, indicating a potential 45.67% downside.</li>
<li>Healthpeak Properties is maintaining an Outperform status according to analysts, with an average 1-year price target of $24.29, indicating a potential 79.97% downside.</li>
<li>As per analysts' assessments, Omega Healthcare Invts is favoring an Neutral trajectory, with an average 1-year price target of $42.2, suggesting a potential 65.2% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Ventas, Healthpeak Properties and Omega Healthcare Invts, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>7.40%</td>
<td>$549.48M</td>
<td>0.23%</td>
</tr>
<tr>
<td>Ventas</td>
<td>Outperform</td>
<td>8.55%</td>
<td>$519.18M</td>
<td>0.20%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>27.31%</td>
<td>$413.85M</td>
<td>1.65%</td>
</tr>
<tr>
<td>Omega Healthcare Invts</td>
<td>Neutral</td>
<td>1.02%</td>
<td>$249.00M</td>
<td>3.15%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Alexandria Real Estate ranks in the middle for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity among its peers.</p>
<h3>Unveiling the Story Behind Alexandria Real Estate</h3>
<p>Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.</p>
<h3>Financial Insights: Alexandria Real Estate</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Alexandria Real Estate's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>7.4%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Alexandria Real Estate's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.6%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Alexandria Real Estate's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.23%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Alexandria Real Estate's ROA excels beyond industry benchmarks, reaching <strong>0.11%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.7</strong>.</p>
<p><a href="https://www.benzinga.com/quote/ARE/earnings"><strong>To track all earnings releases for Alexandria Real Estate visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Alexandria Real Estate's Earnings Preview

<p>Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Guaranty Bancshares will report an <strong>earnings per share</strong> (EPS) of $0.60.</p>
<p>Anticipation surrounds Guaranty Bancshares's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.11, which was followed by a 4.17% increase in the share price the next day.</p>
<p>Here's a look at Guaranty Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.47</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.65</td>
<td>0.58</td>
<td>0.51</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275813_0.png" alt="eps graph" /></p>
<h3>Guaranty Bancshares Share Price Analysis</h3>
<p>Shares of Guaranty Bancshares were trading at $35.58 as of October 17. Over the last 52-week period, shares are up 29.53%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GNTY/earnings"><strong>To track all earnings releases for Guaranty Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GNTY

Guaranty Bancshares's Earnings Outlook

<p>KKR Real Estate Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that KKR Real Estate Finance will report an <strong>earnings per share</strong> (EPS) of $0.34.</p>
<p>The announcement from KKR Real Estate Finance is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 14.57% increase in the share price on the following day.</p>
<p>Here's a look at KKR Real Estate Finance's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.66</td>
<td>0.34</td>
<td>0.11</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.57</td>
<td>0.39</td>
<td>-0.37</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>15.0%</td>
<td>-2.0%</td>
<td>-14.000000000000002%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275806_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of KKR Real Estate Finance were trading at $12.0 as of October 17. Over the last 52-week period, shares are up 19.38%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/KREF/earnings"><strong>To track all earnings releases for KKR Real Estate Finance visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KREF

What's Next: KKR Real Estate Finance's Earnings Preview

<p><strong>Cathay General</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Cathay General will report an <strong>earnings per share</strong> (EPS) of $0.95. </p>
<p>The announcement from Cathay General is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.65% increase in the share price on the subsequent day.</p>
<p>Here's a look at Cathay General's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.98</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.25</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275799_0.png" alt="eps graph" /></p>
<h3>Market Performance of Cathay General's Stock</h3>
<p>Shares of Cathay General were trading at $46.61 as of October 17. Over the last 52-week period, shares are up 38.83%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CATY/earnings"><strong>To track all earnings releases for Cathay General visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CATY

A Preview Of Cathay General's Earnings

<p>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Medpace Hldgs will report an <strong>earnings per share</strong> (EPS) of $2.80.</p>
<p>The market awaits Medpace Hldgs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.21, leading to a 18.27% drop in the share price on the subsequent day.</p>
<p>Here's a look at Medpace Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.54</td>
<td>2.46</td>
<td>2.22</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.75</td>
<td>3.20</td>
<td>2.46</td>
<td>2.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>8.0%</td>
<td>12.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275745_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Medpace Hldgs were trading at $342.89 as of October 17. Over the last 52-week period, shares are up 55.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Medpace Hldgs</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Medpace Hldgs.</p>
<p>Analysts have provided Medpace Hldgs with 10 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $395.6, suggesting a potential 15.37% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Bio-Techne, Charles River and Bio-Rad Laboratories, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>For Bio-Techne, analysts project an Buy trajectory, with an average 1-year price target of $82.33, indicating a potential 75.99% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Charles River, with an average 1-year price target of $203.75, suggesting a potential 40.58% downside.</li>
<li>As per analysts' assessments, Bio-Rad Laboratories is favoring an Neutral trajectory, with an average 1-year price target of $378.4, suggesting a potential 10.36% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Bio-Techne, Charles River and Bio-Rad Laboratories, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>14.59%</td>
<td>$153.84M</td>
<td>12.31%</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>Buy</td>
<td>1.59%</td>
<td>$203.35M</td>
<td>1.99%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>Neutral</td>
<td>-6.26%</td>
<td>$355.12M</td>
<td>-27.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Medpace Hldgs ranks in the middle among its peers for revenue growth, with positive growth compared to some peers. It is at the top for gross profit, indicating strong profitability. However, its return on equity is lower than some peers, suggesting room for improvement in utilizing shareholder equity effectively. Overall, Medpace Hldgs shows a balanced performance compared to its peers in these key financial metrics.</p>
<h3>Delving into Medpace Hldgs's Background</h3>
<p>Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.</p>
<h3>Understanding the Numbers: Medpace Hldgs's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Medpace Hldgs displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>14.59%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Medpace Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>16.73%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>12.31%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.76%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Medpace Hldgs's debt-to-equity ratio is below the industry average at <strong>0.17</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/MEDP/earnings"><strong>To track all earnings releases for Medpace Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MEDP

Insights Ahead: Medpace Hldgs's Quarterly Earnings

<p>Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Cadence Bank to report an <strong>earnings per share</strong> (EPS) of $0.64.</p>
<p>Anticipation surrounds Cadence Bank's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 3.93% increase in the share price the next day.</p>
<p>Here's a look at Cadence Bank's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.61</td>
<td>0.55</td>
<td>0.53</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.62</td>
<td>0.40</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>4.0%</td>
<td>-6.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275738_0.png" alt="eps graph" /></p>
<h3>Performance of Cadence Bank Shares</h3>
<p>Shares of Cadence Bank were trading at $33.5 as of October 17. Over the last 52-week period, shares are up 68.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CADE/earnings"><strong>To track all earnings releases for Cadence Bank visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Cadence Bank's Future Earnings

<p><strong>BOK Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BOK Financial will report an <strong>earnings per share</strong> (EPS) of $1.98. </p>
<p>The market awaits BOK Financial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.32, leading to a 0.74% drop in the share price the following trading session.</p>
<p>Here's a look at BOK Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>1.73</td>
<td>1.75</td>
<td>2.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.02</td>
<td>1.91</td>
<td>1.76</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275725_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of BOK Financial were trading at $114.66 as of October 17. Over the last 52-week period, shares are up 57.6%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BOKF/earnings"><strong>To track all earnings releases for BOK Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BOK Financial's Earnings Outlook

Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosciences Inc. reported a net and comprehensive loss of $2,028,505 for t...

Bright Minds Biosciences Financial Struggles Continue

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Bright Minds Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/drug-stock-quote/"><strong>DRUG</strong></a></span>) just reported results for the third quarter of 2024.</p><ul><li>Bright Minds Biosciences reported earnings per share of 5 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/drug-stock-earnings-bright-minds-biosciences-for-q3-of-2024/">DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024

Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD

Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report

Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosciences has launched the Phase 2 BREAKTHROUGH Study to assess its nove...

Bright Minds Trials New Epilepsy Drug in Phase 2

Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosciences, a trailblazer in CNS disorder treatments, is set to present t...

Bright Minds Biosciences Spotlights CNS Innovations at Key Conferences

Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosciences has announced that its management is unaware of any significan...

Bright Minds Biosciences Sees Unexplained Market Activity

Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosciences has announced promising preclinical results for its compound B...

Bright Minds' BMB-201 Shows Promise in Pain Relief

Bright Minds rally ends as psychedelic stocks extend volatility

Bright Minds rebounds after $35M private placement

ATAI

ATNF

CMND

CMPS

CYBN

DRUG

ENVB

GHRS

MNMD

RVVTF

SEEL

SPRC

Press Releases

Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

News

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

"Peraso Inc. (NASDAQ: PRSO) Revolutionizes Consumer Experiences with Game-Changing mmWave Technology" more stocks inside….

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

Comments

Bright Minds Biosciences

Notizie

Ultime notizie per Bright Minds Biosciences (NASDAQ:DRUG) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO